Agility Robotics Announces Executive Leadership Appointments
Agility Robotics has appointed three new members to its executive leadership team to support its public company operations and growth strategy.
Stocks · News reference
Analysts initiated coverage on KE, MBX, ENSC, DORM and AGLT, issuing mostly Buy/positive ratings with new price targets.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Agility Robotics has appointed three new members to its executive leadership team to support its public company operations and growth strategy.
Filed: 2026-11-17 AccNo: 0001606757-26-000084 Size: 1 MB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Ensysce Biosciences announced its financial results for the third quarter ended September 30, 2026, highlighting the impact of its recent Cy Biopharma acquisition and progress in its clinical pipeline.
UBS has initiated research coverage on Ensysce Biosciences with a Buy rating and a price target of $2.00.
Filed: 2026-11-12 AccNo: 0001493152-26-051414 Size: 284 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Investment firm HC Wainwright has initiated research coverage on MBX Biosciences, assigning the stock a 'Buy' rating and a price target of $90.